header-logo header-logo

06 November 2015
Issue: 7675 / Categories: Case law , Law digest , In Court
printer mail-detail

Patent

Teva UK Ltd v Boehringer Ingelheim Pharma GmbH & Co KG [2015] EWHC 2963 (Pat), [2015] All ER (D) 214 (Oct)

The Chancery Division held that an application brought by the defendant pharmaceutical company, Boehringer Ingelheim Pharma GmbH & Co KG, to introduce new claims to a patent dispute would be dismissed, where the proposed use of a drug, to be used in a dry powder inhaler for the delivery of tiotropium bromide to the lung of a patient suffering from chronic obstructive pulmonary disease or asthma, was obvious and the new claims revealed no inventive step.

If you are not a subscriber, subscribe now to read this content
If you are already a subscriber sign in
...or Register for two weeks' free access to subscriber content

MOVERS & SHAKERS

Clyde & Co—Suriya Ashok

Clyde & Co—Suriya Ashok

Clyde Co strengthens energy transition and construction offering with hire of Suriya Ashok

Jurit—Nicole Gallop Mildon

Jurit—Nicole Gallop Mildon

Jurit appoints rare dual-qualified lawyer to expand Anglo-French private wealth expertise

NEWS
The Supreme Court has settled a long-running dispute over part-time workers: unfavourable treatment need be a significant or effective cause, not the sole cause
Arbitration may be private, but its confidentiality is no impenetrable shield. Writing in NLJ this week, James Glaysher of Kingsley Napley examines when courts will permit arbitral material to surface in open litigation
The Financial Reporting Council’s revised Audit Enforcement Procedure will alter the balance of power in corporate investigations
A telecoms operator may be able to hold over under the Landlord and Tenant Act 1954, yet still be unable to secure a renewal: an outcome described as a legal ‘paradox’

Safety fears do not automatically justify shutting an interested person out of a statutory will application

back-to-top-scroll